マルファン症候群治療の世界市場：2024年～2031年

概要

世界のマルファン症候群治療市場は、2023年に2億350万米ドルに達し、2031年には3億1,260万米ドルに達すると予測され、予測期間2024-2031年のCAGRは5.6%で成長する見込みです。

マルファン症候群は、結合組織（体内の臓器やその他の構造を支え固定する繊維）に影響を及ぼす遺伝性疾患です。マルファン症候群は最も一般的に心臓、目、血管、骨格に影響を及ぼします。治療は罹患部位によって異なり、薬物療法、その他の治療法、手術療法などが行われます。調査と治療・手術の進歩により、マルファン症候群の患者も生産的で長生きできるようになった。

市場力学：

促進要因と抑制要因

研究開発の増加

研究開発の増加は、予測期間中に市場全体が成長するための主要な促進要因の1つです。研究開発は、新規画像診断法、治療標的、機械学習モデルを通じて、マルファン症候群の理解と治療を進めています。

例えば、2023年5月には、フィブロネクチンがマルファン症候群（MFS）患者の大動脈瘤を治療できる可能性を示唆する研究が発表されました。この調査は、MFSのインテグリンa5B1が炎症反応の増幅に関与していることを示しており、大動脈瘤の新しい治療法を示唆しています。

症候群に伴う副作用

マルファン症候群は体の様々な部位に影響を及ぼし、他の問題や合併症を発症する可能性があります。例えば、体の主動脈（大動脈）の拡大（動脈瘤）です。大動脈の壁が裂けたり破裂したりすると、命にかかわる緊急事態となります。白内障は、目の水晶体に濁りが生じる病気です。硬膜外反症は、脊髄を包む組織が弱くなって伸びることで起こる。

市場セグメント分析

世界のマルファン症候群治療市場は、治療タイプ、投与経路、エンドユーザー、地域によって区分されます。

治療タイプ別では、大動脈拡張がマルファン症候群治療薬市場シェアの約37.3％を占めています。

治療タイプ別では大動脈拡張が約37.3％を占めるマルファン症候群は、多くの臓器系に影響を及ぼす比較的一般的な結合組織の遺伝性疾患であるが、最も重篤な合併症は大動脈瘤と解離です。心血管系合併症の管理には、内科的および外科的な様々なアプローチが利用可能です。

例えば、2022年8月、マルファン財団によると、マルファン症候群患者1442人が参加した7つの世界的臨床試験のメタアナリシスにより、アンジオテンシン受容体拮抗薬（ARB）が患者の大動脈基部拡大率を有意に減少させることが明らかになった。ロサルタンやイルベサルタンなどのARBは、すでにβ遮断薬を服用している患者においても有効でした。特に、疾患の原因となるFBN1遺伝子変異を有する患者において、大動脈基部拡大率を減少させる効果が顕著であり、生物学的な裏付けが得られました。

市場地域別シェア

北米は、予測期間を通じて市場全体の約38.4%を占めると予測される

北米は、米国におけるマルファン症候群の有病率の上昇、治療オプションの進歩、FDAの承認、新規製品の発売などの要因により、予測期間を通じて市場シェア全体の約38.4%を占めると予測されます。

例えば、Children's Wisconsinでは、米国では推定50,000人がマルファン症候群に罹患しています（5,000人に3人）。マルファン症候群は男女同数で発症し、またすべての人種・民族に等しく見られます。生後20,000人に1人の割合で発症します。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 研究開発の活発化
    • 慢性疾患の増加
  • 抑制要因
    • 本症に伴う副作用
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• 特許分析
• PESTLE分析
• SWOT分析
• DMIオピニオン

第6章 治療タイプ別

• 大動脈拡張
• β遮断薬
• カルシウム拮抗薬
• ACE遮断薬
• 大動脈基部置換術
• 弁温存大動脈基部置換術
• 解離や動脈瘤に対する複雑な大動脈手術
• その他

第7章 投与経路別

• 経口
• 非経口
• その他

第8章 エンドユーザー別

• 病院
• 診療所
• その他

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第11章 企業プロファイル

• Mesa Science Associates Inc
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Merck & Co. Inc
• Aurobindo Pharma USA
• Teva Pharmaceuticals
• Lupin Pharmaceuticals, Inc
• AdvaCare Pharma（*LIST NOT EXHAUSTIVE）

第12章 付録

Overview

Global Marfan Syndrome Treatment Market reached US$ 203.5 million in 2023 and is expected to reach US$ 312.6 million by 2031, growing at a CAGR of 5.6% during the forecast period 2024-2031.

Marfan syndrome is an inherited disorder that affects connective tissue the fibres that support and anchor the organs and other structures in the body. Marfan syndrome most commonly affects the heart, eyes, blood vessels, and skeleton. Treatment varies depending on the area of the body affected and may include medications, other therapies, and surgery to manage the condition and its complications. Research and advances in treatments and surgeries allow people with Marfan syndrome to live long, productive lives.

Market Dynamics: Drivers & Restraints

Rise in research and development

The rise in research and development is one of the major driving factors that help the overall market to grow during the forecast period. Research and development are advancing the understanding and treatment of Marfan syndrome through novel imaging methods, therapeutic targets, and machine-learning models.

For instance, in May 2023, a study suggested that fibronectin can potentially treat aortic aneurysms in individuals with Marfan Syndrome (MFS). The research indicates that integrin a5B1 in MFS is responsible for amplifying inflammatory responses, suggesting a new treatment approach for aortic aneurysms.

Side effects associated with the syndrome

Marfan syndrome affects different areas of the body, other problems and complications can develop, including, enlargement (aneurysm) of the main artery in the body (aorta), which happens when the wall of the aorta weakens and bulges. It is a life-threatening emergency if the wall of the aorta tears or ruptures. Cataracts are cloudy areas in the lens of the eye. Dural ectasia happens when the tissue that surrounds the spinal cord weakens and stretches.

Market Segment Analysis

The global Marfan syndrome treatment market is segmented based on treatment type, route of administration, end-user, and region.

The aortic dilation from the treatment type segment accounted for approximately 37.3% of the Marfan syndrome treatment market share

The aortic dilation from the treatment type segment accounted for approximately 37.3%. Marfan syndrome is a relatively common heritable disorder of connective tissue that affects numerous organ systems, but the most severe complication is aortic aneurysm and dissection. A variety of medical and surgical approaches are available for managing the cardiovascular complications.

For instance, in August 2022, according to the Marfan Foundation, a meta-analysis of seven global clinical trials involving 1442 participants with Marfan syndrome found that angiotensin receptor blockers (ARBs) significantly reduce the rate of aortic root enlargement in patients. The study found that ARBs, such as losartan and irbesartan, were effective even among those already taking beta-blockers. The rate-reducing effect was particularly significant among patients with a disease-causing FBN1 gene mutation, providing biological support for the effect.

Market Geographical Share

North America is estimated to hold about 38.4% of the total market share throughout the forecast period

North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to factors like the rise in the prevalence of Marfan syndrome in the United States, advancement in treatment options, FDA approvals, novel product launches, and other factors help the region to grow during the forecast period.

For instance, in Children's Wisconsin, an estimated 50,000 people in the United States have Marfan syndrome (or three out of every 5,000 people). Marfan syndrome occurs in equal numbers in males and females and also appears equally in all races and ethnic groups. It occurs in one in 20,000 live births.

Market Segmentation

By Treatment Type

Aortic Dilation

Beta Blocker

Calcium Channel Blocker

ACE Blocker

Aortic root replacement

Valve sparing root replacement

Complex aortic surgery for dissections and aneurysms

Others

By Route of Administration

Oral

Parenteral

Others

By End-User

Hospitals

Clinics

Others

By Region

North America

The U.S.

Canada

Mexico

Europe

Germany

UK

France

Italy

Spain

Rest of Europe

South America

Brazil

Argentina

Rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Market Competitive Landscape

The major global players in the market include Mesa Science Associates Inc., Merck & Co. Inc., Aurobindo Pharma USA, Teva Pharmaceuticals, Lupin Pharmaceuticals, Inc., and AdvaCare Pharma among others.

Key Developments

In November 2023, a Pune team of eye surgeons at a city hospital successfully restored normal vision in a 35-year-old woman living with Marfan syndrome, a genetic disorder affecting connective tissue the fibers that support and anchor organs and other structures in the human body.

Why Purchase the Report?

To visualize the global Marfan syndrome treatment market segmentation based on treatment type, route of administration, end-user, and region as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development.

Excel data sheet with numerous data points of the Marfan syndrome treatment market level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping available as Excel consisting of key products of all the major players.

The global Marfan syndrome treatment market report would provide approximately 64 tables, 61 figures, and 186 pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Treatment Type
• 3.2. Snippet by Route of Administration
• 3.3. Snippet by End User
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rise in research and development
    • 4.1.1.2. Rise in the prevalence of chronic diseases
  • 4.1.2. Restraints
    • 4.1.2.1. Side effects associated with the syndrome
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Patent Analysis
• 5.6. PESTLE Analysis
• 5.7. SWOT Analysis
• 5.8. DMI Opinion

6. By Treatment Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 6.1.2. Market Attractiveness Index, By Treatment Type
• 6.2. Aortic Dilation*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Beta Blocker
• 6.4. Calcium Channel Blocker
• 6.5. ACE Blocker
• 6.6. Aortic root replacement
• 6.7. Valve sparing root replacement
• 6.8. Complex aortic surgery for dissections and aneurysms
• 6.9. Others

7. By Route of Administration

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 7.1.2. Market Attractiveness Index, By Route of Administration
• 7.2. Oral*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Parenteral
• 7.4. Others

8. By End User

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 8.1.2. Market Attractiveness Index, By End User
• 8.2. Hospitals*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Clinics
• 8.4. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. The U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. UK
    • 9.3.6.3. France
    • 9.3.6.4. Italy
    • 9.3.6.5. Spain
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. South Korea
    • 9.5.6.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Mesa Science Associates Inc *
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. Merck & Co. Inc
• 11.3. Aurobindo Pharma USA
• 11.4. Teva Pharmaceuticals
• 11.5. Lupin Pharmaceuticals, Inc
• 11.6. AdvaCare Pharma (*LIST NOT EXHAUSTIVE)

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us